Chemicon Sublicenses RNAi Technology from Promega

Feb 17, 2004

NEW YORK, Feb. 17 (GenomeWeb News) - Chemicon International has sub-licensed an RNAi technology from Promega, the companies said today.

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.